Lou Hawthorne is founder / CEO of NaNotics, LLC, and inventor of the company’s core technology: NaNots, which are injectable “nano-extractors” capable of ultra-rapid depletion of soluble disease drivers from blood. NaNots – the subject of 12 granted patents to date – essentially invert the drug paradigm by subtracting molecules from the body, rather than adding them as drugs do. Lou is an inventor-entrepreneur with 25+ years of experience founding and leading companies developing new biotechnologies – including reproductive cloning, human IVF, and nanomedicine. Lou has been covered by most major media, including appearances on The Oprah Winfrey Show and Good Morning America. Lou holds a B.A. in English Literature from Princeton University, where he was a University Scholar and recipient of the Ward Mathis prize. Lou still misses Mira – the world's first cloned pet dog – a part of his family till she died in 2020, at almost 13.
NaNots: A New Class of Immunotherapy
NaNots are nanoparticles engineered to deplete soluble targets from blood without engaging cell membrane targets of the same type. For many targets, the soluble form is pathogenic while the membrane form drives essential biologic functions, a distinction drugs cannot generally make. NaNots hold the promise of new, ultra-safe methods of immune modulation.
Ira Mellman, Genentech
Human cells have been successfully used as treatment for blood cancers for decades but translating the promise to cell-based treatment for solid tumors has been slow. The advent of gene-editing techniques such as CRISPR, coupled with advances in our understanding of immunology and optimization of growing, manufacturing, transporting, storing, and handling specialized biological samples and materials is transforming the cell therapy field. We will hear in this session about some of the most promising work in the field, as well as the challenges in overcoming resistance